Literature DB >> 18300573

Coexistence of the antiphospholipid syndrome and abdominal aortic aneurysm.

Martine Szyper-Kravitz1, Arie Altman, Jozélio Freire de Carvalho, Francesca Bellisai, Mauro Galeazzi, Yael Eshet, Yehuda Shoenfeld.   

Abstract

The antiphospholipid syndrome is characterized by recurrent fetal loss, venous and/or arterial thrombosis, and thrombocytopenia associated with elevated titers of lupus anticoagulant and anticardiolipin antibodies. Although thrombosis is the characteristic vascular involvement in APS, the development of vascular aneurysms in patients with APS has been reported. We describe four patients with established APS who developed abdominal aortic aneurysm, and review the literature on previous published cases of arterial aneurysms developing in patients with APS. In addition, we discuss the possible pathophysiological association between APS and the development of this vascular abnormality.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300573

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  4 in total

Review 1.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

Review 2.  Aneurysms in primary antiphospholipid syndrome: a case-based review.

Authors:  Jozélio Freire de Carvalho; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

Review 3.  Cardiovascular risk factors in the antiphospholipid syndrome.

Authors:  Felipe Freire da Silva; Roger Abramino Levy; Jozélio Freire de Carvalho
Journal:  J Immunol Res       Date:  2014-07-13       Impact factor: 4.818

4.  Antiphospholipid antibodies predict progression of abdominal aortic aneurysms.

Authors:  Christina Duftner; Rüdiger Seiler; Christian Dejaco; Iris Chemelli-Steingruber; Harald Schennach; Werner Klotz; Michael Rieger; Manfred Herold; Jürgen Falkensammer; Gustav Fraedrich; Michael Schirmer
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.